264 related articles for article (PubMed ID: 28796556)
41. The emerging role of oncolytic virus therapy against cancer.
Russell L; Peng KW
Chin Clin Oncol; 2018 Apr; 7(2):16. PubMed ID: 29764161
[TBL] [Abstract][Full Text] [Related]
42. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
43. Viruses as nanomedicine for cancer.
Badrinath N; Heo J; Yoo SY
Int J Nanomedicine; 2016; 11():4835-4847. PubMed ID: 27703350
[TBL] [Abstract][Full Text] [Related]
44. Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response.
Wu YY; Sun TK; Chen MS; Munir M; Liu HJ
Front Cell Infect Microbiol; 2023; 13():1142172. PubMed ID: 37009515
[TBL] [Abstract][Full Text] [Related]
45. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
[TBL] [Abstract][Full Text] [Related]
46. Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.
Stiff A; Caserta E; Sborov DW; Nuovo GJ; Mo X; Schlotter SY; Canella A; Smith E; Badway J; Old M; Jaime-Ramirez AC; Yan P; Benson DM; Byrd JC; Baiocchi R; Kaur B; Hofmeister CC; Pichiorri F
Mol Cancer Ther; 2016 May; 15(5):830-41. PubMed ID: 26809490
[TBL] [Abstract][Full Text] [Related]
47. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.
McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA
Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818
[TBL] [Abstract][Full Text] [Related]
48. Progress of oncolytic viruses in sarcomas.
Lettieri CK; Hingorani P; Kolb EA
Expert Rev Anticancer Ther; 2012 Feb; 12(2):229-42. PubMed ID: 22316371
[TBL] [Abstract][Full Text] [Related]
49. Virus, Oncolytic Virus and Human Prostate Cancer.
Liu GB; Zhao L; Zhang L; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115
[TBL] [Abstract][Full Text] [Related]
50. Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.
Mohamed A; Johnston RN; Shmulevitz M
Viruses; 2015 Dec; 7(12):6251-78. PubMed ID: 26633466
[TBL] [Abstract][Full Text] [Related]
51. Oncolytic virotherapy for hematological malignancies.
Bais S; Bartee E; Rahman MM; McFadden G; Cogle CR
Adv Virol; 2012; 2012():186512. PubMed ID: 22312362
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
53. Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.
Meyers DE; Thakur S; Thirukkumaran CM; Morris DG
Blood Cancer J; 2017 Dec; 7(12):640. PubMed ID: 29208938
[TBL] [Abstract][Full Text] [Related]
54. United virus: the oncolytic tag-team against cancer!
Le Boeuf F; Bell JC
Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
[TBL] [Abstract][Full Text] [Related]
55. Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
Turnbull S; West EJ; Scott KJ; Appleton E; Melcher A; Ralph C
Viruses; 2015 Dec; 7(12):6291-312. PubMed ID: 26633468
[TBL] [Abstract][Full Text] [Related]
56. Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.
Stanford MM; McFadden G
Expert Opin Biol Ther; 2007 Sep; 7(9):1415-25. PubMed ID: 17727330
[TBL] [Abstract][Full Text] [Related]
57. Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses.
Bucurescu S
Acta Pharm; 2010 Dec; 60(4):407-13. PubMed ID: 21169133
[TBL] [Abstract][Full Text] [Related]
58. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.
Harrington KJ; Vile RG; Melcher A; Chester J; Pandha HS
Cytokine Growth Factor Rev; 2010; 21(2-3):91-8. PubMed ID: 20223697
[TBL] [Abstract][Full Text] [Related]
59. Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma.
Cook J; Acosta-Medina AA; Peng KW; Lacy M; Russell S
Cancer Treat Res Commun; 2021; 29():100473. PubMed ID: 34673439
[TBL] [Abstract][Full Text] [Related]
60. Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters.
Bailey K; Kirk A; Naik S; Nace R; Steele MB; Suksanpaisan L; Li X; Federspiel MJ; Peng KW; Kirk D; Russell SJ
PLoS One; 2013; 8(9):e73759. PubMed ID: 24040057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
